|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:administered_by
|
subcutaneous injection
|
|
gptkbp:approves
|
gptkb:2002
gptkb:FDA
|
|
gptkbp:available_on
|
pre-filled syringe
autoinjector
|
|
gptkbp:brand
|
gptkb:pegfilgrastim
|
|
gptkbp:class
|
colony-stimulating factors
|
|
gptkbp:clinical_trial
|
Phase III
|
|
gptkbp:contraindication
|
hypersensitivity to pegfilgrastim
|
|
gptkbp:dosage_form
|
injection
|
|
gptkbp:financial_support
|
available
|
|
gptkbp:formulation
|
sterile solution
|
|
gptkbp:frequency
|
once per chemotherapy cycle
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Neulasta
|
|
gptkbp:incompatibilities
|
certain IV solutions
|
|
gptkbp:indication
|
chemotherapy-induced neutropenia
|
|
gptkbp:ingredients
|
gptkb:pegfilgrastim
|
|
gptkbp:interacts_with
|
other chemotherapy drugs
|
|
gptkbp:invention
|
gptkb:2023
|
|
gptkbp:is_monitored_by
|
white blood cell count
|
|
gptkbp:manufacturer
|
gptkb:Amgen
|
|
gptkbp:marketed_as
|
gptkb:Canada
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:mechanism_of_action
|
stimulates bone marrow
|
|
gptkbp:patient_education
|
injection technique
side effects awareness
when to seek medical help
|
|
gptkbp:patient_population
|
cancer patients
|
|
gptkbp:previous_name
|
gptkb:pegfilgrastim
|
|
gptkbp:price
|
high
|
|
gptkbp:provides_guidance_on
|
NCCN guidelines
|
|
gptkbp:related_to
|
gptkb:Neupogen
|
|
gptkbp:requires
|
gptkb:true
|
|
gptkbp:research
|
ongoing
|
|
gptkbp:route_of_administration
|
subcutaneous
|
|
gptkbp:safety_measures
|
blood tests
|
|
gptkbp:shelf_life
|
24 months
|
|
gptkbp:side_effect
|
fatigue
headache
nausea
allergic reactions
acute respiratory distress syndrome
bone pain
thrombocytopenia
leukocytosis
splenic rupture
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:used_for
|
preventing infections
|
|
gptkbp:bfsParent
|
gptkb:Amgen
|
|
gptkbp:bfsLayer
|
4
|